EU lists rare nerve disorder as side-effect of J&J COVID-19 vaccine

1 minute read

Vials labelled "COVID-19 Coronavirus Vaccine" and sryinge are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

Register now for FREE unlimited access to Reuters.com

July 22 (Reuters) - Europe's medicines regulator said on Thursday it had added a rare nerve-degenerating disorder, Guillain-Barré syndrome, as a possible rare side effect from Johnson & Johnson's (JNJ.N) COVID-19 vaccine after it reviewed 108 cases reported worldwide.

"After assessing the available data, PRAC considered that a causal relationship between COVID-19 vaccine Janssen and GBS is possible," the European Medicines Agency said, referring to its safety committee, PRAC.

Register now for FREE unlimited access to Reuters.com
Reporting by Pushkala Aripaka in Bengaluru; editing by Uttaresh.V

Our Standards: The Thomson Reuters Trust Principles.